- Home
- KOD vs PRQR Comparison
KOD vs PRQR Comparison
Compare KOD & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- PRQR
- Stock Information
- Founded
- KOD 2009
- PRQR 2012
- Country
- KOD United States
- PRQR Netherlands
- Employees
- KOD N/A
- PRQR N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- PRQR Health Care
- Exchange
- KOD Nasdaq
- PRQR Nasdaq
- Market Cap
- KOD 198.4M
- PRQR 232.8M
- IPO Year
- KOD 2018
- PRQR 2014
- Fundamental
- Price
- KOD $9.35
- PRQR $1.99
- Analyst Decision
- KOD Hold
- PRQR Strong Buy
- Analyst Count
- KOD 4
- PRQR 8
- Target Price
- KOD $11.75
- PRQR $8.88
- AVG Volume (30 Days)
- KOD 556.4K
- PRQR 378.7K
- Earning Date
- KOD 11-13-2025
- PRQR 11-06-2025
- Dividend Yield
- KOD N/A
- PRQR N/A
- EPS Growth
- KOD N/A
- PRQR N/A
- EPS
- KOD N/A
- PRQR N/A
- Revenue
- KOD N/A
- PRQR $20,129,184.00
- Revenue This Year
- KOD N/A
- PRQR N/A
- Revenue Next Year
- KOD N/A
- PRQR N/A
- P/E Ratio
- KOD N/A
- PRQR N/A
- Revenue Growth
- KOD N/A
- PRQR 8.65
- 52 Week Low
- KOD $1.92
- PRQR $1.07
- 52 Week High
- KOD $11.60
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- KOD 52.81
- PRQR 37.36
- Support Level
- KOD $8.91
- PRQR $2.21
- Resistance Level
- KOD $10.20
- PRQR $2.50
- Average True Range (ATR)
- KOD 0.75
- PRQR 0.15
- MACD
- KOD -0.12
- PRQR -0.03
- Stochastic Oscillator
- KOD 45.49
- PRQR 4.63
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.